Cite

HARVARD Citation

    Petzold, A. et al. (2022). Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma. European journal of cancer. pp. 42-53. [Online]. 
  
Back to record